Literature DB >> 8478076

Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

X X Gu1, C M Tsai.   

Abstract

A method was developed for coupling carboxylic acid-containing oligosaccharides (OS) to proteins. An OS was isolated from Neisseria meningitidis group A strain A1 lipooligosaccharide (LOS). This LOS has no human glycolipid-like lacto-N-neotetraose structure and contains multiple immunotypes, including L8, found in group B and C strains. The carboxylic acid at 2-keto-3-deoxyoctulosonic acid of the OS was linked through adipic acid dihydrazide to tetanus toxoid. The molar ratio of the OS to tetanus toxoid in three conjugates ranged from 11:1 to 19:1. The antigenicity of the OS was conserved in these conjugates, as measured by an enzyme-linked immunosorbent assay (ELISA) and an inhibition ELISA with polyclonal and monoclonal antibodies to A1 LOS. These conjugates induced immunoglobulin G antibodies to A1 LOS in mice and rabbits. The immunogenicity of the conjugates in rabbits was enhanced by use of monophosphoryl lipid A plus trehalose dimycolate as an adjuvant. The resulting rabbit antisera cross-reacted with most of 12 prototype LOSs and with LOSs from two group B disease strains, 44/76 and BB431, in an ELISA and in Western blotting (immunoblotting), which revealed a 3.6-kDa reactive band in these LOSs. The rabbit antisera showed bactericidal activity against homologous strain A1 and heterologous strains 44/76 and BB431. These results indicate that conjugates derived from A1 LOS can induce antibodies against many LOS immunotypes from different organism serogroups, including group B. OS-protein conjugates derived from meningococcal LOSs may therefore be candidate vaccines to prevent meningitis caused by meningococci.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478076      PMCID: PMC280778          DOI: 10.1128/iai.61.5.1873-1880.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978.

Authors:  E Holten
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

2.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

3.  Prospects for the prevention of meningococcal disease: special reference to group B.

Authors:  C E Frasch
Journal:  Vaccine       Date:  1987-03       Impact factor: 3.641

4.  Structure and immunochemistry of meningococcal lipopolysaccharides.

Authors:  H J Jennings; M Beurret; A Gamian; F Michon
Journal:  Antonie Van Leeuwenhoek       Date:  1987       Impact factor: 2.271

5.  Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

6.  Outer-membrane protein and lipopolysaccharide serotyping of Neisseria meningitidis by inhibition of a solid-phase radioimmunoassay.

Authors:  W D Zollinger; R E Mandrell
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

7.  Immunotype epitopes of Neisseria meningitidis lipooligosaccharide types 1 through 8.

Authors:  C M Tsai; L F Mocca; C E Frasch
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

8.  Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.

Authors:  S J Cryz; A B Lang; J C Sadoff; R Germanier; E Fürer
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.609

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  13 in total

1.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Phenotypic and transcriptional characterization of the meningococcal PhoPQ system, a magnesium-sensing two-component regulatory system that controls genes involved in remodeling the meningococcal cell surface.

Authors:  J Newcombe; J C Jeynes; E Mendoza; J Hinds; G L Marsden; R A Stabler; M Marti; J J McFadden
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

3.  Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.

Authors:  X X Gu; C M Tsai; T Ueyama; S J Barenkamp; J B Robbins; D J Lim
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

6.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

7.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

8.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

9.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 10.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.